Objective: To assess the cross-sectional association of thiazolidinediones with diabetic macular edema (DME).
D

IABETIC MACULAR EDEMA
(DME) is one of the main causes of visual impairment in persons with diabetic retinopathy. A small number of case reports have raised the possibility that use of thiazolidinediones, which can cause fluid retention, generally, might exacerbate DME. 1, 2 These observations led to physician alerts or label changes by manufacturers in Canada and the United States. [3] [4] [5] [6] One report 1 described a patient who developed vision loss and DME after an increase in the dosage of rosiglitazone maleate from 2 to 8 mg/d. After the dosage was reverted to 2 mg/d, the vision of the patient improved and his DME resolved itself. Ryan et al 2 reported results from a retrospective medical record review of 30 patients who sought care at a single practice of retinal specialists with use of pioglitazone hydrochloride or rosiglitazone and both lower-extremity edema and DME. The authors contended that fluid overload owing to use of thiazolidinediones contributed to DME in at least 19 of 30 patients and that, in 2 patients, there was evidence of a direct cause-and-effect relationship. Finally, a case report 7 of macular edema being resolved with systemic furosemide suggests that thiazolidinediones may exacerbate macular edema. In a larger study of 292 patients, Shen et al 8 found no association of rosiglitazone with DME.
These reports are limited by the absence of comparison groups of patients who have not been exposed to thiazolidinediones and cannot control for confounding between thiazolidinedione exposure and other risk factors for DME, such as sex, 9 age, 9 ethnicity, 10 long-standing diabetes, 9, 11 insulin use, 12 increased severity of diabetic retinopathy, 9, 11 elevated serum cholesterol level, [13] [14] [15] [16] hypertension, 9 and poor glycemic control. 9, 11 Interest in this issue has been heightened by broader concerns about the safety of the currently available thiazolidine-diones, pioglitazone and rosiglitazone. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) Study, 17 which tested the hypothesis that pioglitazone can reduce cardiovascular risk, showed not only benefit in an important secondary cardiovascular end point but also significant increases of both peripheral edema and congestive heart failure. A meta-analysis 18 of trials of pioglitazone suggested reductions of cardiovascular death, myocardial infarction, and stroke but also increased risk of congestive heart failure. Rosiglitazone has been associated in another meta-analysis 19 [21] [22] [23] [24] [25] ensued. The Food and Drug Administration now requires that the package label for pioglitazone include a black-box warning about risk of congestive heart failure and that the package label for rosiglitazone include a similar warning about the risk of congestive heart failure or myocardial ischemia. 26 The Eye Substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 27 trial was designed to test the effect of the ACCORD interventions (strategies to control blood glucose levels, blood lipid levels, and blood pressure) on the development and progression of diabetic retinopathy. This study provides us with the opportunity to evaluate the potential association of thiazolidinediones with DME. In addition, we report the relationship between thiazolidinedione use and visual acuity, which is assessed in all participants enrolled in the ACCORD study.
METHODS
The ACCORD study 28, 29 and the ACCORD Eye Substudy have been described previously. In brief, ACCORD is a multicenter, randomized, controlled, double, 2ϫ2 factorial trial with 10 251 patients with type 2 diabetes. The trial was designed to test the effects of intensive glycemia control, treatment to increase highdensity lipoprotein cholesterol levels and lower levels of triglycerides, and intensive blood pressure control on major cardiovascular disease. Visual acuity was assessed at baseline in 9690 people by means of a standardized Early Treatment Diabetic Retinopathy Study (ETDRS) logarithmic chart. 30 The ACCORD Eye Substudy recruited 3537 participants in whom baseline stereoscopic retinal photographs of 7 standard fields were obtained and ophthalmologic examinations were performed between October 23, 2003, and March 10, 2006 . Participants were eligible to enroll in the ACCORD Eye Substudy if they had not undergone laser photocoagulation or vitrectomy for diabetic retinopathy in either eye. A summary of recruitment of ACCORD participants into the ACCORD Eye Substudy is shown in the Figure. Masked evaluators (including B.A.E.) at the Fundus Photograph Reading Center (University of Wisconsin, Madison) graded all photographs for the severity of diabetic retinopathy and the presence of DME. The severity of diabetic retinopathy was graded by means of the ETDRS letter scale 31 and categorized into the following 5 levels using the International Clinical Diabetic Retinopathy Severity scale: none, mild, moderate nonproliferative, severe nonproliferative, and proliferative. 32 We scored DME separately for each eye on a scale of 0 through 3: 0, none; 1, questionable; 2, zone of retinal thickness 1 disc area or greater and within 1 disc diameter or less from the center of the macula; and 3, retinal thickness or adjacent hard exudates within 500 µm of the center of the macula. This scale was collapsed into absence (0) or presence (1-3) of DME. Those eyes graded as levels 2 or 3 would be considered to have clinically significant macular edema (CSME) because the center of the fovea is involved or threatened. 33 Thiazolidinedione use was assessed on the basis of selfreport at the baseline examination and included current use of rosiglitazone or pioglitazone on a regular basis. The duration of thiazolidinedione exposure before baseline is not known, but the ACCORD inclusion criteria required that no new antihyperglycemic drugs were added within 3 months of baseline.
Ethnicity was categorized into nonexclusive categories of white, African American/African Canadian, and Hispanic. Other therapy for diabetes, a surrogate for severity, was measured by the number of types of diabetes medications used at baseline, with the exclusion of thiazolidinediones and insulin. These medications included (1) sulfonylureas, (2) ␣-glucosidase inhibitors, (3) biguanides, and (4) meglitinides. The number of medications ranged from 0 through 4 and was treated as a categorical variable. Insulin and diuretic use at baseline were recorded. Mean arterial pressure was calculated as
Pretibial edema in either foot was assessed at the time of clinical examination. A history of foot ulcer that required antibiotics or presence of ulceration on either foot by examina- tion was documented. Foot amputation secondary to diabetes was assessed by examination.
All analyses were prespecified before analysis began. Descriptive statistics were calculated, with the inclusion of proportions for categorical variables and means, medians, standard deviations, and ranges for continuous variables. Comparisons of proportions between 2 groups were made by means of a 2 test. Almost all participants had measurements performed for both eyes. To account for the withinparticipant correlation and thus to use data from both eyes, our primary model was a generalized estimating equation model 34, 35 that predicted DME, with thiazolidinedione use at baseline as a predictor. The ORs, P values, and 95% CIs are reported. P values were calculated using generalized score statistics, and the CIs presented are Wald intervals. Six factors known to be associated with DME were included as covariates: hemoglobin A 1c (HbA 1c ) level, 9,11 diabetes duration, 9,11 retinopathy severity, 9,11 sex, 9 age, 9 and ethnicity. 10 In a secondary analysis, a modified version of the model selection approach presented by Hosmer and Lemeshow 36 was used to examine other potential covariates ( Table 1 and Table 2 ). Included in all models were thiazolidinedione use at baseline, sex, ethnicity, diabetes duration, age, HbA 1c level, and retinopathy. All other variables were examined for possible inclusion by means of the variable selection method described herein. Three interactions of thiazolidinedione use were specified a priori and were examined in order: thiazolidinedione use with diabetes duration, insulin use (only if insulin was in the model as a main effect), and HbA 1c level. We screened potential covariates at PՅ.25 in a series of unadjusted models and compared patients who used thiazolidinedione with those who did not. These variables and those in the primary model were included, and backward selection (PϾ.10) was used to delete variables from this model. Linearity was examined by means of generalized additive models 37, 38 and by categorization of the covariates at their quartiles. Interactions were examined at PՅ.05. Model adequacy was examined via the techniques of Lin et al 39, 40 to assess linearity and adequacy of the logit link. We examined 2 additional sets of generalized estimating equation models: one for moderate or severe CSME (defined as scores of 2 or 3) and another for severe CSME (defined as a score of 3). The relationship of baseline visual acuity with thiazolidinedione exposure was analyzed with a mixed model of covariance with HbA 1c level, diabetes duration, sex, and age. A random effect for individual was used to account for within-person correlation. Table 1 gives the baseline characteristics of the 3473 participants included in the primary analysis. No adjustment for multiple testing was made. These results are presented as guides to potential relationships. A difference in pretibial edema prevalence was observed by exposure to thiazolidinediones (PϽ .001). Eye-specific prevalence of DME and retinopathy on the 6875 eyes included in the primary analysis are presented by thiazolidinedione exposure in Table 2 . All subsequent results use both eyes in statistical models accounting for correlation.
RESULTS
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The analyses are summarized in Table 3 . In the unadjusted analysis, thiazolidinedione was not associated with DME. The primary analysis provided consistent results. Retinopathy and age were associated with, and HbA 1c level marginally associated with, DME. There was evidence that the relationship of HbA 1c level to DME was nonlinear, but this evidence had no effect on the estimated effect of thiazolidinedione (data not shown). After the variable selection procedure described herein for the secondary analysis, 4 additional variables were added to the primary model: the logarithm of triglyceride level, cholesterol level, the logarithm of the albumin-creatinine ratio, and smoking status. There was no association between thiazolidinedione use and DME. Those who formerly and currently smoked had lower prevalence of DME than did those who never smoked (with smoking status determined by self-report). Interestingly, the association of HbA 1c level with DME was attenuated from the primary (OR,1.15; P=.06) to the secondary model (OR,1.08; P=. 29) , perhaps because of confounding by other variables. As in the primary analysis, there was evidence that the relationship between HbA 1c level and DME was nonlinear (data not shown). When we fit the HbA 1c level as a 4-level category, the estimated association between thiazolidinedione use and DME was essentially unchanged (data not shown). When the primary and unadjusted models were refit by the use of only the data available for the secondary model, the results were substantially unchanged (data not shown). The examination of outcomes other than any DME (ie, moderate-severe or severe) did not substantially change the results in any model (data not shown).
VISUAL ACUITY
In the adjusted analysis, thiazolidinedione use was associated with marginally better visual acuity (0.79 letter; 95% CI for the difference in means, 0.20-1.38; P=.009) in 9690 participants (19 239 eyes). That is, those who used thiazolidinediones before baseline had, on average, visual acuity scores less than 1 letter (0.79) better on the 0 to 100 scale. Diabetes duration (␤=−0.18 per year; 95% CI, −0.21 to −0.15; P Ͻ .001), HbA 1c level (␤=−0.85 per 1%; 95% CI, −1.08 to −0.63; P Ͻ.001), female sex (␤=−2.66; 95% CI, −3.14 to −2.18; P Ͻ.001), and age (␤ = −0.28 per year; 95% CI, −0.32 to −0.25; PϽ.001) were all inversely associated with visual acuity. That is, a 10-year-longer diabetes duration is associated with a worse visual acuity by 1.8 ETDRS letters. Similarly, a 10-year-older age is associated with worse acuity by 2.8 letters. A 1% higher HbA 1c level (Ͼ7.5%, the lower inclusion limit) is associated with a worse acuity by 0.85 letter. That is, a 2% greater HbA 1c level is approximately equivalent to a 10-year-older age (1.9 vs 1.8 letters). Thiazolidinedione use is approximately equivalent to a 3-year-younger age (0.79 vs 0.84). In an unadjusted model in 9795 participants (19 446 eyes), the association between visual acuity and use of thiazolidinedione was similar (0.90 letter; 95% CI, 0.30-1.51; P=.004).
COMMENT
Thiazolidinedione use was not associated with the presence of CSME or any DME among ACCORD participants at baseline. The ACCORD Eye Substudy provided ( an opportunity to examine the relationship in a large sample with a comparable untreated group in whom retinopathy, with the inclusion of DME, was graded in a standardized fashion by a centralized reading center. Visual acuities were also measured in all patients by means of a common protocol. The analyses enabled adjustment for information with regard to multiple potential confounding variables collected in a standardized protocol.
These findings are reassuring in that they do not support concern based on the case reports of DME associated with thiazolidinedione use. However, this analysis has limitations. Perhaps longer-term exposure to a thiazolidinedione is necessary for risk to develop; we only know that participants had thiazolidinedione exposure for at least 3 months. It is also possible that there is an idiosyncratic association between thiazolidinedione use and DME that occurs rarely. As others 9,11 have previ- a Because of the slight differences between the Wald confidence intervals and the generalized score statistics used for P values, there is an apparent discrepancy between the confidence interval and P value; we prefer the generalized score test over the Wald test.
b Natural logarithm used as a predictor. The primary model was prespecified and included factors known to be associated with macular edema.
ously reported, we observed relationships between DME and each of the following: HbA 1c level, retinopathy, and age. We were unable to confirm previous reports of associations of DME with diabetes duration, 9,11 sex, 9 and ethnic category, 10 perhaps because participants who had undergone previous laser photocoagulation, which represents the most severe end of the retinopathy scale, were excluded from the ACCORD Eye Substudy. In addition, participation in the ACCORD trial was restricted to people with fairly advanced diabetes, many of whom had a fairly long duration of diabetes at randomization; thus, we may not have the ability to detect an association with diabetes duration.
Adverse associations were found between DME and elevated cholesterol level and nonsmoking status, and beneficial associations were found between DME and greater albumin-creatinine ratio and a higher level of triglycerides. Others 16 have reported an association between DME and both triglyceride and cholesterol levels.We believe the adverse relationship between DME and triglyceride levels seen in this study may be owing to the high collinearity between cholesterol and triglyceride levels. The biological plausibility that those who currently and had formerly smoked would have a lower prevalence of DME is unclear and is perhaps attributable to chance or the inclusion process for the ACCORD Study, although the results are consistent with the unadjusted analysis (data not shown). However, a previous study 41 showed an association between high-risk proliferative diabetic retinopathy and smoking, a result that is contrary to those for DME in this study. There was evidence of a positive association (0.79 letter) between thiazolidinedione exposure and visual acuity. We do not know whether this finding is clinically significant.
The exclusion criteria of the ACCORD Eye Substudy of previous laser photocoagulation or vitrectomy for diabetic retinopathy may have limited our analysis because laser photocoagulation is also a type of therapy for DME. It is possible that some ACCORD participants with lasertreated DME would have been excluded from the ACCORD Eye Substudy, which would result in decreased power to detect an association. Unfortunately, no data with regard to DME were collected in these participants. The possibility that recent prior exposure to thiazolidinedione in some patients in the control group could potentially weaken any differences between groups cannot be excluded but seems unlikely because that exposure, if any, should have ended at least 3 months before baseline. However, no association was observed between concurrent thiazolidinedione exposure and any type of eye surgery, with the inclusion of retinal laser photocoagulation and vitrectomy at baseline (data not shown).
The cross-sectional analysis presented herein is likely to be less informative than an examination of incident macular edema, which will be possible at the end of ACCORD, at which point the dose and duration of thiazolidinedione exposure during the period between baseline and follow-up photographs can be examined. Other additional covariates could include postbaseline values of HbA 1c and fasting plasma glucose levels and exposure to insulin, diuretics, calcium channel blockers, oral steroids, niacin and nicotinic acid, and nonsteroidal antiinflammatory drugs. The current analysis also does not take into account duration of exposure, past exposure, or type of thiazolidinedione (rosiglitazone or pioglitazone), which could be important causal considerations.
Many recent clinical trials of DME have used optical coherence tomography-measured central retinal thickness as an end point, which was not used in this study. Historically, DME measured from stereoscopic fundus photographs has been well accepted as a clinical end point and is moderately correlated with optical coherence tomography measurements; 42 therefore, results would not likely have been different with the use of optical coherence tomography.
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